The role of ErbB4 in cance r
ConclusionsHere, we discuss the role of ErbB4 in normal physiology and in breast, lung, colorectal, gastric, pancreatic, prostate, bladder, and brain cancers, as well as in hepatocellular carcinoma, cholangiocarcinoma, and melanoma. Understanding the role of ErbB4 in cancer is not only important for the treatment of tumors, but also for the treatment of other disorders in which ErbB4 plays a major role, e.g. cardiovascular disease.
Publication date: Available online 30 May 2020Source: Life SciencesAuthor(s): Qi Fu, Zhenhai Yu
Publication date: Available online 29 May 2020Source: Life SciencesAuthor(s): Xiaoping Pan, Chen Wang, Yan Li, Lida Zhu, Ti Zhang
Publication date: Available online 29 May 2020Source: Life SciencesAuthor(s): Nagesh Kishan Panchal, E.P. Sabina
In this study, five machine learning algorithms and twelve types of molecular fingerprints were employed to generate QSAR discriminant models for mitochondrial toxicity. A threshold moving method was adopted to resolve the imbalance issue in the training data. Consensus of the models by an averaging probability strategy improved prediction performance. The best model has correct classification rates of 81.8% and 88.3% in ten-fold cross validation and external validation, respectively. Substructures such as phenol, carboxylic acid, nitro and arylchloride were found informative through analysis of information gain and freque...
Publication date: Available online 30 May 2020Source: Urology Case ReportsAuthor(s): Andrew Moe, Isaac Thyer, Rajalingam Sinniah, Dickon Hayne
This study is aimed at determining the prevalence of severe depression in Iranian women with breast...
Publication date: Available online 30 May 2020Source: European Journal of Surgical OncologyAuthor(s): R.H. Bhogal, P.H. Patel, S.L.F. Doran, S. Zar, J.M. Pollok, L.R. Jiao, W.H. Allum, M.A. Chaudry, S. Kumar
Publication date: Available online 29 May 2020Source: Respiratory InvestigationAuthor(s): Yoshiaki Kinoshita, Hiroshi Ishii, Yoshinobu Eishi, Keisuke Uchida, Masayo Yoshimura, Akinori Iwasaki, Masaki Fujita, Kazuki Nabeshima, Kentaro Watanabe
This study aimed to evaluate the effects of LLV on HCC development, mortality, and cirrhotic complications among patients according to their adherence to entecavir (ETV) treatment. Methods: We performed a retrospective observational analysis of data from 894 consecutive adult patients with treatment-naïve CHB undergoing ETV treatment. LLV was defined according to either persistent or intermittent episodes of
Conclusions: After sorafenib failure, the use of nivolumab may be associated with improved OS and better objective response rate as compared to using regorafenib. PMID: 32460459 [PubMed - as supplied by publisher]
More News: Bile Duct Cancer | Bladder Cancer | Brain | Brain Cancers | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Cardiology | Cardiovascular | Cholangiocarcinoma | Colorectal Cancer | Gastric (Stomach) Cancer | Gastroenterology | Heart | Hepatocellular Carcinoma | Liver Cancer | Melanoma | Neurology | Pancreas | Pancreatic Cancer | Physiology | Skin Cancer